NASDAQ:VCYT

Veracyte Stock Forecast, Price & News

$53.57
-1.47 (-2.67 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$53.16
Now: $53.57
$57.97
50-Day Range
$44.47
MA: $52.84
$62.89
52-Week Range
$21.19
Now: $53.57
$86.03
Volume518,027 shs
Average Volume1.00 million shs
Market Capitalization$3.59 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.77
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc.; and Bayer AG. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Veracyte logo

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VCYT
CUSIPN/A
Phone650-243-6300
Employees320
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$120.37 million
Book Value$4.90 per share

Profitability

Net Income$-12,600,000.00

Miscellaneous

Market Cap$3.59 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

Headlines

Veracyte (NASDAQ:VCYT) Trading Up 7%
April 13, 2021 |  americanbankingnews.com
3 Cancer Diagnostic Monster Stocks on Sale
April 11, 2021 |  finance.yahoo.com
Veracyte (NASDAQ:VCYT) Shares Gap Down to $53.37
April 9, 2021 |  americanbankingnews.com
Veracyte (NASDAQ:VCYT) Shares Gap Up to $52.72
April 5, 2021 |  americanbankingnews.com
Veracyte (NASDAQ:VCYT) Trading 6.4% Higher
March 31, 2021 |  americanbankingnews.com
Veracyte (NASDAQ:VCYT) Sees Strong Trading Volume
March 25, 2021 |  americanbankingnews.com
Veracyte (NASDAQ:VCYT) Stock Price Down 7.1%
March 24, 2021 |  americanbankingnews.com
Veracyte (NASDAQ:VCYT) Stock Price Down 7.1%
March 24, 2021 |  americanbankingnews.com
Veracyte (NASDAQ:VCYT) Trading Up 6.4%
March 22, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.19 out of 5 stars

Medical Sector

921st out of 2,019 stocks

Medical Laboratories Industry

16th out of 39 stocks

Analyst Opinion: 2.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$53.57
-1.47 (-2.67 %)
(As of 04/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VCYT News and Ratings via Email

Sign-up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Veracyte (NASDAQ:VCYT) Frequently Asked Questions

Is Veracyte a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Veracyte stock.
View analyst ratings for Veracyte
or view top-rated stocks.

What stocks does MarketBeat like better than Veracyte?

Wall Street analysts have given Veracyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Veracyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Veracyte's next earnings date?

Veracyte is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Veracyte
.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) posted its quarterly earnings data on Wednesday, February, 17th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.05. The biotechnology company earned $34.54 million during the quarter, compared to analysts' expectations of $34.53 million. Veracyte had a negative trailing twelve-month return on equity of 12.27% and a negative net margin of 30.46%.
View Veracyte's earnings history
.

How has Veracyte's stock been impacted by Coronavirus (COVID-19)?

Veracyte's stock was trading at $23.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VCYT stock has increased by 127.5% and is now trading at $53.57.
View which stocks have been most impacted by COVID-19
.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte updated its fourth quarter 2020 Pre-Market earnings guidance on Wednesday, February, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $34-35 million, compared to the consensus revenue estimate of $33.49 million.

What price target have analysts set for VCYT?

8 equities research analysts have issued 12-month price targets for Veracyte's shares. Their forecasts range from $48.00 to $88.00. On average, they expect Veracyte's stock price to reach $66.14 in the next year. This suggests a possible upside of 23.5% from the stock's current price.
View analysts' price targets for Veracyte
or view top-rated stocks among Wall Street analysts.

Who are Veracyte's key executives?

Veracyte's management team includes the following people:
  • Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 63, Pay $1.16M)
  • Mr. Keith S. Kennedy C.F.A., CPA, CFA, CPA, CFO & COO (Age 51, Pay $866.97k)
  • Dr. Giulia C. Kennedy Ph.D., Chief Scientific & Medical Officer (Age 62, Pay $677.7k)
  • Mr. John Walter Hanna Jr., Chief Commercial Officer and GM of Endocrinology, Breast Cancer & Lymphoma (Age 40, Pay $583.3k)
  • Mr. Mark Ho, Principal Accounting Officer (Age 48)
  • Mr. Ashish Kheterpal, Chief Information Officer
  • Ms. Tracy Morris, VP of Corp. Communications & Investor Relations
  • Mr. James H. Erlinger III, Exec. VP, Gen. Counsel & Sec. (Age 63)
  • Ms. Jessica Meng, VP of Marketing
  • Dr. Alfred Bowie Jr., VP of Corp. & Bus. Devel.

Who are some of Veracyte's key competitors?

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Who are Veracyte's major shareholders?

Veracyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include Calamos Advisors LLC (0.08%), EFG Asset Management Americas Corp. (0.01%), Phoenix Wealth Advisors (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, John Walter Hanna, Jr, Keith Kennedy, Kevin K Gordon, Mark Ho and Robert S Epstein.
View institutional ownership trends for Veracyte
.

Which institutional investors are selling Veracyte stock?

VCYT stock was sold by a variety of institutional investors in the last quarter, including Phoenix Wealth Advisors, and Pacer Advisors Inc.. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, John Walter Hanna, Jr, Keith Kennedy, Kevin K Gordon, Mark Ho, and Robert S Epstein.
View insider buying and selling activity for Veracyte
or view top insider-selling stocks.

Which institutional investors are buying Veracyte stock?

VCYT stock was acquired by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, and EFG Asset Management Americas Corp..
View insider buying and selling activity for Veracyte
or or view top insider-buying stocks.

How do I buy shares of Veracyte?

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $53.57.

How much money does Veracyte make?

Veracyte has a market capitalization of $3.59 billion and generates $120.37 million in revenue each year. The biotechnology company earns $-12,600,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does Veracyte have?

Veracyte employs 320 workers across the globe.

What is Veracyte's official website?

The official website for Veracyte is www.veracyte.com.

Where are Veracyte's headquarters?

Veracyte is headquartered at 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]


This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.